Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (3): 278-283.doi: 10.35541/cjd.20210259

• Reviews • Previous Articles     Next Articles

Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors

Yang Yongting1, Li Tingting2, Kang Xiaojing2   

  1. 1Graduate School of Xinjiang Medical University, Urumqi 830054, China; 2Department of Dermatology and Venereology, People′s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Dermatologic Diseases, Xinjiang Key Laboratory of Dermatology Research(XJYS1707), Urumqi 830001, China
  • Received:2021-03-26 Revised:2021-10-22 Online:2023-03-15 Published:2023-03-06
  • Contact: Kang Xiaojing
  • Supported by:
    Xinjiang Uygur Autonomous Region Key R&D Program(2021B03001-1)

Abstract: 【Abstract】 Recently, great breakthroughs have been made in immune checkpoint inhibitors for the treatment of melanoma. However, only a small proportion of patients show a long-lasting response to immunotherapy, and risks of immune-related adverse events and drug resistance have been also increasing along with the emergence of combination treatment. This review summarizes biomarkers related to the efficacy of immune checkpoint inhibitors in the treatment of melanoma, aiming to predict and screen out patients who may benefit from immunotherapy, guide individualized clinical treatment, and reduce the occurrence of drug resistance and adverse reactions.

Key words: Nevi and melanoma, Tumor microenvironment, Immune checkpoint inhibitors, Tumor mutation burden, Peripheral blood biomarkers, Gut microbiota